Fig 1: Schematic illustration of RPL22 contributing to the pathogenesis of psoriasis. In psoriasis patients, hyperacetylation of histone H3K27 in the promoter region of RPL22 in the skin lesions of psoriasis patients induces RPL22 overexpression, overexpressed RPL22 up-regulates CyclinD1 expression to promote the KCs proliferation and enhancing CXCL10 expression to induce CD4+ T cells chemotaxis, Both of them secrete cytokines including IL-23, IL-6, IL-1β and IL-17a to aggravate the occurrence and development of psoriasis.
Fig 2: Association analysis of Drp1 and RPL22 in human gastric adenocarcinoma. (a) Association between Drp1 and RPL22 in human gastric adenocarcinoma and normal tissues was determined by the GEPIA2 database. Association between Drp1 and RPL22 in gastric mixed adenocarcinoma tissues (b), gastric intestinal-type adenocarcinoma tissues (c), and diffuse gastric adenocarcinoma tissues (d) was analyzed using gene expression profiles downloaded from the TCGA. R, relative coefficient.
Fig 3: RPL22 expression is elevated in skin lesions of IMQ mouse models. (A) The protein expression level of RPL22 in lesional skins from IMQ-exposed mice and vehicle-exposed mice. (B) The statistical analysis of the relative mRNA (left panel, n = 5) and protein expression levels (right panel, n = 3) of RPL22 in lesional skins from IMQ-exposed mice and vehicle-exposed mice. (C) IHC staining of RPL22 in lesional skins from IMQ-exposed mice vehicle-exposed mice. (D) The mRNA expression level of RPL22 in psoriatic-like cells model on HaCaT cells stimulating with a cocktail of cytokines including Oncostatin-M, IL-1α, IL-17A, IL-22, and TNF-α(M5). Data (D) are representative of at least 3 independent experiments. Data represent the mean ± SEM. *P < 0.05. Two-tailed unpaired Student’s t test was used.
Fig 4: RPL22 promotes the proliferation of HaCaT cells and inhibits apoptosis of KCs. (A) Selection and verification of RPL22 siRNA intervention efficiency in HaCaT cells (n = 3). (B) Overexpression efficiency verification of RPL22 overexpressed plasmid (OE-RPL22) in HaCaT cells (n = 3). (C) Microscopy to observe cell proliferation state in HaCaT cells at 72hours. (D) CCK-8 assay to detect the cell proliferation level in HaCaT cells transfected with si-RPL22 or OE-RPL22 and their controls. (E) Flow cytometry to detect the apoptosis of KCs transfected with si-RPL22 or OE-RPL22 and their controls (n = 3). (F) Statistical analysis data to show the difference of four groups at 48 hours. All data are representative of at least 3 independent experiments. Data represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS, not significant. Two-tailed unpaired Student’s t test was used.
Fig 5: RPL22 expression is elevated in skin lesions of psoriasis patients. (A) The protein expression level of RPL22 in skin lesions derived from psoriasis patients and healthy controls. (B) The statistical analysis of the relative mRNA (left panel, n = 23) and protein expression levels(right panel, n = 7) of RPL22 in skin lesions derived from psoriasis patients and healthy controls. (C) IHC staining of RPL22 in skin lesions derived from psoriasis patients and healthy controls. (D) Correlation of human RPL22 mRNA expression in psoriatic skin with PASI scores (n = 23). Data represent the mean ± SEM. **P < 0.01, ***P < 0.001. Two-tailed unpaired Student’s t test was used.
Supplier Page from Abcam for Anti-RPL22 antibody